2026 Dose-Escalation Watchdog

Henry Meds High Dose Surcharge Audit (2026)

By Claire Bennett, MA • Medically Reviewed by Dr. James Nakamura, MD • Updated November 2026 • 8 min read
$297–$397
Henry Meds monthly Semaglutide cost ($100/mo extra above 1.0mg)
$449–$549
Henry Meds monthly Tirzepatide cost ($5,388–$6,588/year)
$49 / $99
Losing Weight RX flat rate on ALL doses up to 2.4mg & 15mg

Our 2026 Henry Meds high dose surcharge audit documents how monthly costs climb at maintenance doses, compared with Losing Weight RX's flat-rate $49/mo semaglutide across all doses. When comparing Henry Meds vs. Losing Weight RX in 2026, the biggest hidden cost trap is Henry Meds' high-dose surcharge policy. While Henry Meds advertises $297/month for compounded Semaglutide and $449/month for compounded Tirzepatide, those prices only cover low starter and mid-tier doses.

Once a Henry Meds patient titrates above 1.0mg/week of Semaglutide (to the clinical STEP-1 maintenance doses of 1.7mg or 2.4mg) or above 10mg/week of Tirzepatide, Henry Meds tacks on an extra $100/month high-dose surcharge—pushing monthly bills to $397/month for Semaglutide and $549/month for Tirzepatide.

Black Friday Early Access · 83% OFF

Stop Paying Henry Meds $297–$549/mo: Lock In $49 Semaglutide & $99 Tirzepatide

Henry Meds charges $297/mo for starter Semaglutide and penalizes you an extra $100/month ($397/mo) once you reach therapeutic 1.7mg–2.4mg doses. Losing Weight RX charges $49/mo flat (Semaglutide) and $99/mo flat (Tirzepatide) across every dose tier.

Claim $49 Semaglutide Rate → Claim $99 Tirzepatide Rate →

Why High-Dose Penalties Are Unjustified in 503A Compounding

  1. The Titration Trap: Clinical trials prove most sustainable weight loss occurs at maintenance doses (1.7mg–2.4mg Semaglutide and 10mg–15mg Tirzepatide). Penalizing patients $100/mo right when they reach effective dosages adds $1,200/year to an already inflated $297–$449 base price.
  2. Losing Weight RX Zero-Escalation Guarantee: Whether you are on 0.25mg starter Semaglutide or 2.4mg maintenance (or 2.5mg to 15mg Tirzepatide), your rate stays strictly locked at $49/month (Semaglutide) and $99/month (Tirzepatide).

Head-to-Head Comparison: Henry Meds vs. Losing Weight RX

Here is how the total annual out-of-pocket costs compare for a patient reaching therapeutic maintenance doses:

Feature / Cost Tier Henry Meds Losing Weight RX
Monthly Platform / Membership Fee $100/mo High-Dose Surcharge $0 (Free)
Semaglutide Monthly Total (All Doses) $297/mo (Jumps to $397/mo >1mg) $49 / month flat rate
Tirzepatide Monthly Total (All Doses) $449/mo (Jumps to $549/mo high dose) $99 / month flat rate
Dose Escalation Price Hikes Flat medication fee, but high base No dose penalties
Pharmacy Quality Standard 503A State-Licensed 503A State-Licensed & Tested
12-Month Out-of-Pocket (Semaglutide) $4,164 – $6,188 total $588 total (Save $1,548/yr)

Why Patients Are Leaving Subscription-Based Telehealth

Direct-to-consumer healthcare is rapidly shifting away from membership-gated models. Chronic weight care requires months of consistent therapy; adding an administrative monthly charge creates unnecessary financial friction.

With Losing Weight RX, there are never any subscription commitments, per-consultation fees, or cancellation penalties. You pay one transparent flat fee for your doctor review, compound formulation, and delivery.

Frequently Asked Questions

Does Henry Meds charge extra for higher doses of Semaglutide and Tirzepatide?

Yes. Henry Meds charges an additional $100/month once your prescription exceeds 1.0mg/week of Semaglutide ($397/mo total) or standard tiers of Tirzepatide ($549/mo total).

Does Losing Weight RX ever increase the price when my dose goes up?

Never. Losing Weight RX guarantees flat-rate pricing across all dosage strengths: $49/month for Semaglutide (0.25mg through 2.4mg) and $99/month for Tirzepatide (2.5mg through 15mg).

Can I switch from Henry Meds to Losing Weight RX if I'm already on 2.0mg or 2.4mg?

Yes! Upload your current Henry Meds vial photo during our 2-minute intake and our U.S. physician will match your exact high-dose protocol at the flat $49/mo or $99/mo rate.

Get Started with $0 Membership Fees →

2026 Verified GLP-1 Cash-Cost & U-100 Syringe Unit Benchmark

Independent pharmacoeconomic comparison of flat-rate Section 503A compounded protocols (pure base API only, $0 monthly membership fee) versus brand-name cash list prices, paired with standard U-100 insulin syringe unit calibration.

Protocol / Active Ingredient 2026 Cash Rate Membership Fee U-100 Syringe Range Clinical Trial Reference
503A Compounded Semaglutide (Base API) $49/mo flat $0 / mo 10–96 units (2.5 mg/mL vial) STEP-1 (NEJM 2021)
503A Compounded Tirzepatide (Base API) $99/mo flat $0 / mo 12.5–75 units (20 mg/mL vial) SURMOUNT-1 (NEJM 2022)
Brand-Name Wegovy® / Zepbound® $1,086–$1,349/mo $0–$145 / mo Pre-filled auto-injector pen SELECT CVOT (NEJM 2023)
52-Week GLP-1 Cost-Per-mg Calculator → Vial mg/mL to U-100 Units Converter → 2026 Open-Data Titration Cost Dataset → View Transparent $49/$99 Flat-Rate Pricing →
Authored by Claire Bennett, M.S. · Medically Reviewed by Dr. Elena Rivera, M.D.
Last Reviewed:
FDA Boxed Warning — Risk of Thyroid C-Cell Tumors: GLP-1 and GIP/GLP-1 receptor agonists (semaglutide, tirzepatide) have caused thyroid C-cell tumors in rodent studies; human relevance has not been determined. Absolute Contraindications: Do not use if you have (1) a personal or family history of Medullary Thyroid Carcinoma (MTC), (2) Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), (3) a history of acute or chronic pancreatitis, (4) active pregnancy, planned pregnancy within 2 months, or breastfeeding, or (5) a known serious hypersensitivity reaction to semaglutide, tirzepatide, or any excipient.

Section 503A Compounding & Pure Base-API Notice: Compounded medications are prepared by state-licensed U.S. Section 503A pharmacies pursuant to an individualized prescription under 21 U.S.C. § 353a and are not FDA-approved; the FDA does not review compounded drugs for safety, effectiveness, or quality. Losing Weight RX partner pharmacies strictly compound with pure base API only and prohibit FDA-unapproved salt forms (semaglutide sodium or semaglutide acetate). Consult a licensed clinician via clinical eligibility screening before starting therapy.

Clinical & Regulatory References

The clinical efficacy, dosing, safety, and regulatory information in Henry Meds High Dose Surcharge Audit (2026) is supported by the following peer-reviewed studies and authoritative .gov / .edu sources:

  1. Asiabar, A. S., Rezaei, M. A., Jafarzadeh, D., Rajaei, S., Atefimanesh, P., Soleimanpour, S., Meher, M. H. K., & Azari, S. (2024). The cost-effectiveness analysis of semaglutide for the treatment of adult and adolescent patients with overweight and obesity: a systematic review. European journal of clinical pharmacology, 80(12), 1857-1870. https://doi.org/10.1007/s00228-024-03755-w
  2. Betensky, D. J., Smith, K. C., Katz, J. N., Yang, C., Hunter, D. J., Collins, J. E., Feldman, C. H., Messier, S. P., Kim, J. S., Selzer, F., Paltiel, A. D., & Losina, E. (2025). The Cost-Effectiveness of Semaglutide and Tirzepatide for Patients With Knee Osteoarthritis and Obesity. Annals of internal medicine, 178(11), 1549-1560. https://doi.org/10.7326/ANNALS-24-03609
  3. National Institute of Diabetes and Digestive and Kidney Diseases. (2023). Prescription medications to treat overweight and obesity. https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity
  4. U.S. Food and Drug Administration. (2025). FDA drug shortages database. https://www.accessdata.fda.gov/scripts/drugshortages/default.cfm
  5. UCLA Health. (2024). Semaglutide for weight loss: What you need to know. https://www.uclahealth.org/news/article/semaglutide-weight-loss-what-you-need-know
  6. Wang, S., Fan, D., Yao, Q., & Sun, X. (2025). The cost-utility and budget impact analyses of Tirzepatide versus once-weekly Semaglutide as add-on therapy to metformin in patients with type 2 diabetes mellitus in China. Diabetes, obesity & metabolism, 27(9), 5269-5279. https://doi.org/10.1111/dom.16580